Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | December 11, 2012 | December 13, 2012 |
| AbbVie Inc.ABBV · Entity 2800 | Vice Chairman | February 25, 2022 | March 01, 2022 |
| CrowdStrike Holdings, Inc.CRWD · Entity 1172 | Director | September 18, 2026 | September 22, 2026 |
| GENERAL DYNAMICS CORPGD · Entity 2916 | Director | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 11, 2012 · Filed December 13, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 179,338 |
Ending reported balance
After 2012-12-11 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2012-12-11 · Exercise / conversion · Acquired 36,985 · Balance 216,323 Row 2 · 2012-12-11 · Exercise / conversion · Acquired 67,200 · Balance 283,523 Row 3 · 2012-12-11 · Exercise / conversion · Acquired 1,045 · Balance 284,568 Row 4 · 2012-12-11 · Exercise / conversion · Acquired 2,395 · Balance 286,963 Row 5 · 2012-12-11 · Exercise / conversion · Acquired 652 · Balance 287,615 Row 6 · 2012-12-11 · Exercise / conversion · Acquired 11,500 · Balance 299,115 Row 7 · 2012-12-11 · Sale · Disposed 119,777 · Balance 179,338 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.34 · Expires 2015-02-17 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2012-12-11 · Exercise / conversion · Disposed 36,985 · Balance 0 F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.54 · Expires 2017-02-15 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2012-12-11 · Exercise / conversion · Disposed 67,200 · Balance 0 F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.16 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2012-12-11 · Exercise / conversion · Disposed 1,045 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.74 · Expires 2014-02-19 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2012-12-11 · Exercise / conversion · Disposed 2,395 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.01 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2012-12-11 · Exercise / conversion · Disposed 652 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.60 · Expires 2021-02-17 | Direct | 38,333 |
Reported balance
After 2012-12-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2012-12-11 · Exercise / conversion · Disposed 11,500 · Balance 38,333 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.
F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date February 25, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 248,002 |
Reported balance
After 2022-02-25 transaction · row 1
1 source rowRow 1 · 2022-02-25 · Tax withholding · Disposed 40,490 · Balance 248,002 |
CrowdStrike Holdings, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 38,724 |
Reported balance
After 2026-09-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-18 · Grant · Acquired 68 · Balance 38,724 F1: The shares represent fully vested RSUs issued in lieu of quarterly cash retainer(s) payable under the issuer's Outsider Director Compensation Policy. The RSUs immediately converted into shares of the issuer's Class A Common Stock. F2: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock. F3: Includes shares to be issued in connection with the vesting of one or more RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares represent fully vested RSUs issued in lieu of quarterly cash retainer(s) payable under the issuer's Outsider Director Compensation Policy. The RSUs immediately converted into shares of the issuer's Class A Common Stock.
F2: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock.
F3: Includes shares to be issued in connection with the vesting of one or more RSUs.
GENERAL DYNAMICS CORP
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,792 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 105 · Balance 13,792 F1: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2010 Filed Mar 2, 2010 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,100 | $54.38 | $331,718.00 |
DisclosureSEC source: 0001179110-10-004234 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,108 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,200 | $54.37 | $173,984.00 |
DisclosureSEC source: 0001179110-10-004234 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,208 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,804 | $54.35 | $206,747.40 |
DisclosureSEC source: 0001179110-10-004234 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,408 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 13,230 | $54.12 | $716,007.60 |
DisclosureSEC source: 0001179110-10-004234 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,212 Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 58,000 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001179110-10-003588 · edgar.xml · derivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common shares · 58,000 shares Expires 2020-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,334 on 02/19/2011, 19,333 on 02/19/2012, and 19,333 on 02/19/2013. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003588 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,442 F2 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 39,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003588 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,442 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.49 | $5,449.04 |
DisclosureSEC source: 0001179110-10-003144 · edgar.xml · nonDerivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,842 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $54.49 | $27,245.50 |
DisclosureSEC source: 0001179110-10-003144 · edgar.xml · nonDerivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,942 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,451 | $54.49 | $351,514.99 |
DisclosureSEC source: 0001179110-10-003144 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,442 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,400 | $54.50 | $239,800.00 |
DisclosureSEC source: 0001179110-10-003144 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,893 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,100 | $54.50 | $168,953.10 |
DisclosureSEC source: 0001179110-10-003144 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,293 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,449 | $53.93 | $347,794.57 |
DisclosureSEC source: 0001179110-10-003144 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,393 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 625 | $0.00 Strike: $53.12 | $0.00 |
DisclosureSEC source: 0001179110-10-002725 · edgar.xml · derivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 625 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 625 | $53.27 | $33,293.75 |
DisclosureSEC source: 0001179110-10-002725 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,842 Read SEC document |
| February 10, 2010 Filed Feb 12, 2010 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 625 | $53.12 | $33,200.00 |
DisclosureSEC source: 0001179110-10-002725 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $47.92 | $9,584.02 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 10 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,842 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $47.92 | $62,296.00 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 9 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,042 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $47.91 | $62,283.00 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 8 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,342 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 700 | $47.90 | $33,530.00 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 7 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,642 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 289 | $47.89 | $13,840.21 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,342 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $47.88 | $23,940.00 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,631 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $47.87 | $9,574.04 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,131 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $47.87 | $47,870.00 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,331 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,571 | $47.86 | $266,628.06 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,331 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,207 | $50.58 | $364,530.06 |
DisclosureSEC source: 0001104659-09-013957 · a4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,902 Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 64,900 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011820 · a4.xml · derivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Underlying: Common shares · 64,900 shares Expires 2019-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,634 on 02/20/2010, 21,633 on 02/20/2011, and 21,633 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 45,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011820 · a4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,109 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 17:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $54.12 | $21,648.48 |
DisclosureSEC source: 0001104659-09-010667 · a4.xml · nonDerivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,309 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 17:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $54.12 | $16,236.45 |
DisclosureSEC source: 0001104659-09-010667 · a4.xml · nonDerivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,709 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 17:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,017 | $54.12 | $55,041.06 |
DisclosureSEC source: 0001104659-09-010667 · a4.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,009 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 17:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,295 | $54.11 | $232,411.04 |
DisclosureSEC source: 0001104659-09-010667 · a4.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,026 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 17:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.13 | $10,826.20 |
DisclosureSEC source: 0001104659-09-010667 · a4.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,321 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 17:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,621 | $54.94 | $143,997.74 |
DisclosureSEC source: 0001104659-09-010667 · a4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,521 Read SEC document |
| February 06, 2009 Filed Feb 11, 2009 00:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $57.03 | $5,703.00 |
DisclosureSEC source: 0001104659-09-008065 · a4.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,142 Read SEC document |
| February 06, 2009 Filed Feb 11, 2009 00:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,500 | $57.02 | $142,550.00 |
DisclosureSEC source: 0001104659-09-008065 · a4.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,242 Read SEC document |
| February 06, 2009 Filed Feb 11, 2009 00:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,900 | $57.01 | $222,339.00 |
DisclosureSEC source: 0001104659-09-008065 · a4.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,742 Read SEC document |
| February 06, 2009 Filed Feb 11, 2009 00:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 31,200 | $57.00 | $1,778,400.00 |
DisclosureSEC source: 0001104659-09-008065 · a4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,642 Read SEC document |
| January 30, 2009 Filed Feb 3, 2009 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,983 | $0.00 Strike: $55.66 | $0.00 |
DisclosureSEC source: 0001104659-09-006091 · a4.xml · derivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,983 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2009 Filed Feb 3, 2009 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,983 | $55.72 | $166,212.76 |
DisclosureSEC source: 0001104659-09-006091 · a4.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,842 Read SEC document |
| January 30, 2009 Filed Feb 3, 2009 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,983 | $55.66 | $166,033.78 |
DisclosureSEC source: 0001104659-09-006091 · a4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2008 Filed Sep 5, 2008 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,281 | $0.00 Strike: $59.01 | $0.00 |
DisclosureSEC source: 0001104659-08-057344 · a4.xml · derivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281 Underlying: Common shares · 1,281 shares Expires 2010-02-10 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 03, 2008 Filed Sep 5, 2008 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,086 | $0.00 Strike: $59.01 | $0.00 |
DisclosureSEC source: 0001104659-08-057344 · a4.xml · derivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,086 Underlying: Common shares · 1,086 shares Expires 2013-02-13 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 03, 2008 Filed Sep 5, 2008 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,475 | $0.00 Strike: $46.19 | $0.00 |
DisclosureSEC source: 0001104659-08-057344 · a4.xml · derivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,475 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 03, 2008 Filed Sep 5, 2008 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,250 | $0.00 Strike: $46.19 | $0.00 |
DisclosureSEC source: 0001104659-08-057344 · a4.xml · derivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,250 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 03, 2008 Filed Sep 5, 2008 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,367 | $59.01 | $139,676.67 |
DisclosureSEC source: 0001104659-08-057344 · a4.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,842 Read SEC document |
| September 03, 2008 Filed Sep 5, 2008 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,725 | $46.19 | $125,867.75 |
DisclosureSEC source: 0001104659-08-057344 · a4.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2008 Filed Sep 2, 2008 23:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,918 | $57.43 | $339,870.74 |
DisclosureSEC source: 0001104659-08-056454 · a4.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,484 Read SEC document |
| August 28, 2008 Filed Sep 2, 2008 23:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,197 | $0.00 Strike: $58.16 | $0.00 |
DisclosureSEC source: 0001104659-08-056454 · a4.xml · derivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,197 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 28, 2008 Filed Sep 2, 2008 23:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,197 | $58.24 | $127,953.28 |
DisclosureSEC source: 0001104659-08-056454 · a4.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,402 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.